drugset / Trial / NCT05296577
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of anlotinib combined with vinorelbine in the treatment of HER2- advanced breast cancer.
Timeline
- Start
- 2022-03-22
- Primary completion
- 2024-09-01
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Comparator | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |
| Comparator | Vinorelbine | Small molecule | 30 mg/m2 | Intravenous |